PHBI — Pharmagreen Biotech Balance Sheet
0.000.00%
- $1.73m
- $2.03m
- $0.00m
Annual balance sheet for Pharmagreen Biotech, fiscal year end - September 30th, USD millions except per share, conversion factor applied.
2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | 2024 September 30th | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | ARS | ARS |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 0.012 | 0.025 | 0.008 | 0.001 | 0 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0 | 0 | 0 | 0.001 | 0.001 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 0.266 | 0.373 | 0.209 | 0.033 | 0.009 |
| Net Property, Plant And Equipment | 0 | — | — | — | — |
| Long Term Notes Receivable | |||||
| Total Assets | 0.266 | 0.373 | 0.209 | 0.122 | 0.098 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 3.17 | 2.03 | 1.91 | 2.21 | 3.14 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Liabilities | 3.15 | 2.02 | 1.98 | 2.26 | 3.19 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | -2.89 | -1.65 | -1.78 | -2.13 | -3.09 |
| Total Liabilities & Shareholders' Equity | 0.266 | 0.373 | 0.209 | 0.122 | 0.098 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |